Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).

@article{Nelson1995SuppressionOF,
  title={Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix).},
  author={Laurie Nelson and Victor Y. Fujimoto and Robert B. Jaffe and Stephen Monroe},
  journal={Fertility and sterility},
  year={1995},
  volume={63 5},
  pages={963-9}
}
OBJECTIVE To determine if daily subcutaneous doses of ganirelix will suppress and maintain E2 < or = 30 pg/mL (conversion factor to SI unit, 3.671), the serum profiles of LH and FSH during and after cessation of treatment, the time-course of the resumption of normal ovarian function after ganirelix cessation, and to identify side effects of daily treatment. DESIGN Open-label nonrandomized clinical study. SETTING Normal human volunteers in an academic research center. PATIENTS Women 21 to… CONTINUE READING